## Abstract Our current understanding of breast cancer susceptibility involves mutations in the 2 major genes __BRCA1__ and __BRCA2__, found in about 25% of high‐risk families, as well as few other low penetrance genes such as __ATM__ and __CHEK2__. Approximately two‐thirds of the multiple cases fa
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family
✍ Scribed by Sophie Gad; Ivan Bièche; Michel Barrois; Federica Casilli; Sabine Pages-Berhouet; Catherine Dehainault; Marion Gauthier-Villars; Aaron Bensimon; Alain Aurias; Rosette Lidereau; Brigitte Bressac-de Paillerets; Mario Tosi; Sylvie Mazoyer; Dominique Stoppa-Lyonnet
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 173 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1059-7794
No coin nor oath required. For personal study only.
✦ Synopsis
A large germline deletion removing exons 1 to 22 of the BRCA1 gene has been previously detected using quantitative PCR based methods (QMPSF and real time PCR gene dosage assay) in a woman affected with breast and ovarian cancer. Here, we report its characterisation by using colour bar code on combed DNA of the BRCA1 region. The 5' boundary is located in a Alu Y sequence in NBR1 intron 18 whereas the 3' boundary is located in a Alu Sc sequence in BRCA1 intron 22. This 161 kb deletion encompassing the NBR1, ΨBRCA1, NBR2 and BRCA1 genes is the largest BRCA1 deletion reported so far. No specific phenotype was associated with the hemizygosity of these four genes.
📜 SIMILAR VOLUMES
## Abstract The prevalence of __BRCA1/2__ germ‐line mutations was assessed in a prospective population‐based series of early‐onset breast cancer (BC) patients in France, and the usefulness of a clinical assessment of hereditary BC risk, based on multiple criteria including pedigree structure, was e
## Abstract The aim of this study was to investigate the impact of increased mRNA levels encoding GIRK1 in breast tumours on GIRK protein expression. mRNA levels encoding hGIRK1 and hGIRK4 in the MCF7, MCF10A and MDA‐MB‐453 breast cancer cell lines were assessed and the corresponding proteins detec